1 / 6

Workshop on the future of telematics in pharmaceuticals

Workshop on the future of telematics in pharmaceuticals. Dr Hubertus Cranz Director-General Association of the European Self-Medication Industry (AESGP) 7 avenue de Tervuren B-1040 Brussels. Future of telematics. EC projects, EMEA projects, Member States’ projects:

alea-wallace
Download Presentation

Workshop on the future of telematics in pharmaceuticals

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Workshop on the future of telematics in pharmaceuticals Dr Hubertus Cranz Director-General Association of the European Self-Medication Industry (AESGP) 7 avenue de Tervuren B-1040 Brussels

  2. Future of telematics • EC projects, EMEA projects, Member States’ projects: • need for increased transparency • need for pooling of efforts and for access to information through a central address • Other projects such as the Common Technical Document to be taken into account

  3. General considerations • Need to group the IT projects according to their type/content (not primarily source/origin of maintenance e.g. EC, EMEA etc.) • Need to clarify “galaxy” of all on-going/envisaged, permanent/temporary IT projects • The more sources  the more difficult: identify, track, rank… the information • Excess of acronyms!  “What is what for?” and “what is accessible to whom?”

  4. Issues • Need to centralise/pool all different IT projects: • avoid redundancy of information • avoid multiplicity of sources • save time • improve tracing of the information etc. • Maintenance of information = priority (difficult, time/cost…)

  5. A way forward • Access and availability of information (e.g. pharmacovigilance data for authorities and marketing authorisation holders) • Involvement of trade associations: • in building initiatives • in practical aspects • Industry wishes to invest resources and to contribute to the implementation of different IT strategies (benefit for all parties)

  6. A case study on the national level GERMANY

More Related